宝色股份 reported revenue of ¥0.71B for the period ended 2026-06-30, -3.6% year on year. Net income was ¥0.03B, a 4.0% net margin on a 20.0% gross margin. The largest revenue line is 压力容器 at 91% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.71B | -3.6% |
| Gross profit | ¥0.14B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | -11.9% |
| Gross margin | 20.0% | Net margin 4.0% |
| Revenue Q/Q | -14.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 压力容器 | ¥0.65B | 91.4% |
| 散件及其他 | ¥0.06B | 8.2% |
| 管道、管件 | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.57B | 80.0% |
| R&D | ¥0.03B | 4.8% |
| SG&A | ¥0.06B | 8.6% |
| Tax & other | ¥0.00B | 0.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.53B |
| Total liabilities | ¥1.01B |
| Shareholders' equity | ¥1.52B |
| Equity / assets | 60.0% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | -481% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
汉宇集团 ・ 博济医药 ・ 科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies